|
FY2025
12 months to Sep 30, 2025
|
FY2024
12 months to Sep 30, 2024
|
FY2023
12 months to Sep 30, 2023
|
FY2022
12 months to Sep 30, 2022
|
FY2021
12 months to Sep 30, 2021
|
|
|---|---|---|---|---|---|
| Revenues | |||||
| Costs and expenses: | |||||
| Cost of revenues | |||||
| Research and development expenses | |||||
| Selling, general and administrative expenses | |||||
| Restructuring and other costs | |||||
| Change in fair value of contingent considerations and holdbacks | |||||
| Impairment of long-lived assets | |||||
| Total costs and expenses | |||||
| Loss from operations | |||||
| Gain on sale of business | |||||
| Interest income | |||||
| Interest expense | |||||
| Gain on deconsolidation of subsidiary | |||||
| Other income (expense), net | |||||
| Loss before income taxes | |||||
| Income tax expense | |||||
| Net loss attributable to common stockholders | |||||
| Other comprehensive income (loss): | |||||
| Change in unrealized gain (loss) on investments | |||||
| Foreign currency translation adjustment | |||||
| Comprehensive loss | |||||
| Net loss per share attributable to common stockholders—basic (in dollars per share) | |||||
| Net loss per share attributable to common stockholders—diluted (in dollars per share) | |||||
| Weighted average shares used in computing net loss per share attributable to common stockholders—basic (in shares) | |||||
| Weighted average shares used in computing net loss per share attributable to common stockholders—diluted (in shares) | |||||
Loading...